JP2005529969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005529969A5 JP2005529969A5 JP2004515006A JP2004515006A JP2005529969A5 JP 2005529969 A5 JP2005529969 A5 JP 2005529969A5 JP 2004515006 A JP2004515006 A JP 2004515006A JP 2004515006 A JP2004515006 A JP 2004515006A JP 2005529969 A5 JP2005529969 A5 JP 2005529969A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- pharmaceutical composition
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 229940076144 Interleukin-10 Drugs 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 210000004962 mammalian cells Anatomy 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
Claims (6)
- 請求項１から３８のいずれかに記載の化合物若しくはその薬学的に許容される塩、または請求項３９に記載の組み合わせを含む、薬学的組成物。
- そのような措置を必要とするヒト若しくはヒト以外の動物において体重を減少させ、または脂肪量を低下させるための、請求項１から３８のいずれかに記載の化合物若しくはその薬学的に許容される塩を含む、薬学的組成物。
- 動物において脂肪の分布若しくは含有量を調節するための、請求項１から３８のいずれかに記載の化合物若しくはその薬学的に許容される塩を含む、薬学的組成物。
- 転移性の一次的若しくは二次的腫瘍の阻害および／または治療のための、請求項１から３８のいずれかに記載の化合物若しくはその薬学的に許容される塩を含む、薬学的組成物。
- 哺乳動物細胞若しくは組織における内因性インターロイキン−１０（ＩＬ-10）の産生を増強するための、請求項１から３８のいずれかに記載の化合物若しくはその薬学的に許容される塩を含む、薬学的組成物。
- 哺乳動物細胞若しくは組織における内因性インターロイキン−２（ＩＬ-２）の産生を増強するための、請求項１から３８のいずれかに記載の化合物若しくはその薬学的に許容される塩を含む、薬学的組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0214267A GB0214267D0 (en) | 2002-06-20 | 2002-06-20 | Compound |
| GB0214267.7 | 2002-06-20 | ||
| GB0217506A GB0217506D0 (en) | 2002-07-29 | 2002-07-29 | Compound |
| GB0217506.5 | 2002-07-29 | ||
| PCT/GB2003/002582 WO2004000854A1 (en) | 2002-06-20 | 2003-06-16 | Sulfur-containing phospholipid derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005529969A JP2005529969A (ja) | 2005-10-06 |
| JP2005529969A5 true JP2005529969A5 (ja) | 2006-12-14 |
| JP5008258B2 JP5008258B2 (ja) | 2012-08-22 |
Family
ID=30001967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004515006A Expired - Fee Related JP5008258B2 (ja) | 2002-06-20 | 2003-06-16 | 含硫黄ホスホリピド誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8178713B2 (ja) |
| EP (1) | EP1515978A1 (ja) |
| JP (1) | JP5008258B2 (ja) |
| KR (1) | KR20050061400A (ja) |
| CN (1) | CN100351259C (ja) |
| AU (1) | AU2003278602C1 (ja) |
| CA (1) | CA2490121C (ja) |
| HK (1) | HK1077829A1 (ja) |
| NO (1) | NO20045562L (ja) |
| NZ (1) | NZ537762A (ja) |
| RU (1) | RU2331649C2 (ja) |
| WO (1) | WO2004000854A1 (ja) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO328803B1 (no) | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
| FR2828487B1 (fr) * | 2001-08-09 | 2005-05-27 | Genfit S A | Nouveaux composes derives d'acides gras, preparation et utilisations |
| FR2850870B1 (fr) * | 2003-02-12 | 2006-07-28 | Genfit S A | Utilisation therapeutique de glycerols acyles et de leurs analogues azotes et sulfures |
| US7659242B2 (en) * | 2004-07-19 | 2010-02-09 | Thia Medica As | Composition comprising protein material and compounds comprising non-oxidizable fatty acid entities |
| WO2006086992A2 (en) * | 2005-02-18 | 2006-08-24 | Liplasome Pharma A/S | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
| NO20053519L (no) * | 2005-07-18 | 2007-01-19 | Thia Medica As | Anvendelse av forbindelser som omfatter fettsyrer |
| NO20055541L (no) * | 2005-11-23 | 2007-05-24 | Berge Biomed As | Use of fatty acid analogues |
| EP2469263A1 (en) * | 2006-01-13 | 2012-06-27 | Ventana Medical Systems, Inc. | Biological sample processing composition and method |
| AU2007267612A1 (en) * | 2006-05-26 | 2007-12-06 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted carboxylic acid compounds |
| JP3944864B1 (ja) * | 2006-07-31 | 2007-07-18 | 株式会社Ｊ−オイルミルズ | メタボリックシンドロームの予防および改善用組成物 |
| DE102007051339A1 (de) * | 2007-10-26 | 2009-04-30 | Müller-Enoch, Dieter, Prof. Dr. | Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien |
| EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| BR112012012085A2 (pt) * | 2009-11-21 | 2016-05-17 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| JP6146990B2 (ja) * | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| US20160024125A1 (en) * | 2013-03-11 | 2016-01-28 | Life Science Nutrition As | Natural lipids containing non-oxidizable fatty acids |
| US10293043B2 (en) * | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| CA2966489A1 (en) * | 2014-11-03 | 2016-05-12 | Nicolai Vladimirovich Bovin | Antimicrobial surface treatment |
| CA2981495C (en) | 2015-03-31 | 2023-09-26 | Vertex Pharmaceuticals (Europe) Limited | Deuterated vx-661 |
| CA2999529A1 (en) | 2015-09-25 | 2017-03-30 | Vertex Pharmaceuticals (Europe) Limited | Deuterated cftr potentiators |
| JP2017105824A (ja) * | 2017-02-10 | 2017-06-15 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| CZ308596B6 (cs) * | 2017-04-03 | 2020-12-23 | Ústav molekulární genetiky AV ČR, v. v. i. | Deriváty fosfolipidů a jejich použití jako léčiva |
| US11708331B2 (en) | 2017-12-01 | 2023-07-25 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| JP6664638B1 (ja) * | 2018-04-27 | 2020-03-13 | 株式会社 レオロジー機能食品研究所 | 新規プラズマローゲン誘導体 |
| JP6654223B2 (ja) * | 2018-08-13 | 2020-02-26 | バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド | 重水素化されたｃｆｔｒ増強物質 |
| US20220362151A1 (en) * | 2019-06-11 | 2022-11-17 | Rosi Charni As | Liposome formulation |
| CN110302159B (zh) * | 2019-06-18 | 2021-12-24 | 东南大学 | 一种还原敏感脂质药物组合物及其制备方法和应用 |
| CN110200920B (zh) * | 2019-06-18 | 2022-03-08 | 东南大学 | 一种还原敏感药物组合物及其制备和应用 |
| CN110251485A (zh) * | 2019-07-16 | 2019-09-20 | 东南大学 | 一种氧化敏感药物组合物及其制备和应用 |
| CN110343131A (zh) * | 2019-07-16 | 2019-10-18 | 东南大学 | 一种硫代磷脂化合物及其制备方法 |
| CN118126079A (zh) * | 2024-03-05 | 2024-06-04 | 南开大学 | 硒磷脂化合物及合成方法与脂质体制剂 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2210230A1 (de) | 1972-03-03 | 1973-09-06 | Kolmar Laboratories | Verwendung bestimmter thioaether als antimikrobielle und zytostatische mittel |
| BE809894A (nl) | 1973-01-30 | 1974-07-18 | Antikleursluierstoffen voor fotografische kleurenmaterialen | |
| JPS5531778B2 (ja) | 1973-02-15 | 1980-08-20 | ||
| DE3620685A1 (de) * | 1986-06-20 | 1987-12-23 | Henkel Kgaa | Neue mittel zur abdeckung unverletzter und/oder verletzter bereiche menschlicher oder tierischer haut |
| EP0300797B1 (en) | 1987-07-22 | 1995-10-04 | Roussel Uclaf | Pesticidal compounds |
| FR2631339B1 (fr) | 1988-05-10 | 1990-11-16 | Cird | Nouveaux eicosanoides sulfures et leur application en pharmacie et en cosmetique |
| US5268494A (en) | 1988-05-10 | 1993-12-07 | Centre International De Recherches Dermatologiques C.I.R.D. | Sulphur-containing eicosanoides and their application in pharmacy and in cosmetics |
| GB8813012D0 (en) | 1988-06-02 | 1988-07-06 | Norsk Hydro As | Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals |
| JPH0379659A (ja) * | 1989-08-22 | 1991-04-04 | Mitsubishi Gas Chem Co Inc | 光学用成形材料 |
| WO1991003542A1 (en) * | 1989-09-11 | 1991-03-21 | Kao Corporation | Bleaching composition |
| JP3079659B2 (ja) | 1991-08-07 | 2000-08-21 | 松下電器産業株式会社 | 車載用空気清浄器 |
| US6602861B1 (en) | 1992-04-16 | 2003-08-05 | Research Corporation Technologies, Inc. | Acylated phospholipid drugs |
| US5290960A (en) | 1993-02-25 | 1994-03-01 | The United States Of America As Represented By The Secretary Of The Navy | Diacetylenic phospholipids containing heteroatom near diacetylenic functionality for modulation of microstructure morphology |
| WO1996011908A1 (en) | 1994-10-13 | 1996-04-25 | Peptide Technology Limited | Modified polyunsaturated fatty acids |
| NO952796D0 (no) | 1995-07-14 | 1995-07-14 | Rolf Berge | Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater |
| WO1999058120A1 (en) | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
| AU1830200A (en) * | 1998-11-25 | 2000-06-13 | Vanderbilt University | Cationic liposomes for gene transfer |
| FR2792312B1 (fr) | 1999-04-15 | 2001-06-08 | Oreal | Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation |
| NO328803B1 (no) * | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
| NO20003591L (no) | 2000-07-13 | 2002-01-14 | Thia Medica As | Fettsyreanaloger for behandling av kreft |
| NO20004844L (no) | 2000-09-27 | 2002-05-10 | Thia Medica As | Fettsyre analoger for behandling av proliferative hudsykdommer |
| NO20006008L (no) | 2000-11-28 | 2002-05-29 | Thia Medica As | Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer |
| US20020188023A1 (en) * | 2000-12-12 | 2002-12-12 | Michael Jorgensen | Compound |
| GB0118517D0 (en) * | 2001-07-30 | 2001-09-19 | Mitsubishi Tokyo Pharm Inc | Compound |
| FR2828487B1 (fr) * | 2001-08-09 | 2005-05-27 | Genfit S A | Nouveaux composes derives d'acides gras, preparation et utilisations |
| US7659242B2 (en) * | 2004-07-19 | 2010-02-09 | Thia Medica As | Composition comprising protein material and compounds comprising non-oxidizable fatty acid entities |
-
2003
- 2003-06-16 CN CNB038174340A patent/CN100351259C/zh not_active Expired - Fee Related
- 2003-06-16 WO PCT/GB2003/002582 patent/WO2004000854A1/en active Application Filing
- 2003-06-16 RU RU2005101196/04A patent/RU2331649C2/ru not_active IP Right Cessation
- 2003-06-16 KR KR1020047020760A patent/KR20050061400A/ko active Search and Examination
- 2003-06-16 JP JP2004515006A patent/JP5008258B2/ja not_active Expired - Fee Related
- 2003-06-16 EP EP03740736A patent/EP1515978A1/en not_active Withdrawn
- 2003-06-16 NZ NZ537762A patent/NZ537762A/en not_active IP Right Cessation
- 2003-06-16 US US10/518,427 patent/US8178713B2/en not_active Expired - Fee Related
- 2003-06-16 AU AU2003278602A patent/AU2003278602C1/en not_active Ceased
- 2003-06-16 CA CA2490121A patent/CA2490121C/en not_active Expired - Fee Related
-
2004
- 2004-12-20 NO NO20045562A patent/NO20045562L/no not_active Application Discontinuation
-
2005
- 2005-11-08 HK HK05109932A patent/HK1077829A1/xx not_active IP Right Cessation
-
2011
- 2011-11-23 US US13/303,173 patent/US20120264966A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005529969A5 (ja) | ||
| IL267126B (en) | Isolated human rpe cells and their use for the treatment of retinal degenerative diseases | |
| WO2005030083A3 (en) | Methods and products which utilize n-acyl-l-aspartic acid | |
| JP2003509343A5 (ja) | ||
| Ito et al. | Effect of soft diets on craniofacial growth in mice | |
| JP2004532810A5 (ja) | ||
| JP2004515500A5 (ja) | ||
| EP2289939A3 (en) | PAN-KIR2DL NK-receptor antibodies and their use in diagnostic and therapy | |
| MY144477A (en) | Galenic formulations of organic compounds | |
| IT1252868B (it) | Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico | |
| TW200630326A (en) | Chemical compounds | |
| ZA200705165B (en) | 5HT2c receptor modulator compositions and methods of use | |
| MX2007008614A (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r). | |
| HK1098364A1 (en) | Pellets containing venlafaxine hydrochloride | |
| WO2004054432A3 (en) | Methods and devices for therapeutic treatment cardiac and other pathologies | |
| EP1952809A3 (en) | Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen | |
| TR200002969T2 (tr) | Farmasötik bileşim. | |
| MY137595A (en) | N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide for the treatment of cancer | |
| TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
| AU2003255843A1 (en) | 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain | |
| MX2009006670A (es) | Composicion farmaceutica que usa el aliskiren y el avosentan. | |
| MXPA06000363A (es) | Forma de dosificacion oral de mesilato de saquinavir. | |
| JP2006505577A5 (ja) | ||
| EA200500687A1 (ru) | Применение дистронциевой соли 2-[n,n-ди(карбоксиметил)амино]-3-циано-4-карбоксиметилтиофен-5-карбоновой кислоты при получении лекарственных средств, предназначенных для лечения гастродуоденальной боли | |
| RU2003129233A (ru) | Метрономная схема приема таксана |